362 related articles for article (PubMed ID: 30335946)
21. Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas.
Parekh S; Privé G; Melnick A
Leuk Lymphoma; 2008 May; 49(5):874-82. PubMed ID: 18452090
[TBL] [Abstract][Full Text] [Related]
22. miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma.
Fan Q; Meng X; Liang H; Zhang H; Liu X; Li L; Li W; Sun W; Zhang H; Zen K; Zhang CY; Zhou Z; Chen X; Ba Y
Protein Cell; 2016 Dec; 7(12):899-912. PubMed ID: 27815824
[TBL] [Abstract][Full Text] [Related]
23. Pomalidomide hybrids act as proteolysis targeting chimeras: Synthesis, anticancer activity and B-Raf degradation.
Chen H; Chen F; Pei S; Gou S
Bioorg Chem; 2019 Jun; 87():191-199. PubMed ID: 30901674
[TBL] [Abstract][Full Text] [Related]
24. Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders.
Yang X; Wang Z; Pei Y; Song N; Xu L; Feng B; Wang H; Luo X; Hu X; Qiu X; Feng H; Yang Y; Zhou Y; Li J; Zhou B
Eur J Med Chem; 2021 Jun; 218():113341. PubMed ID: 33780898
[TBL] [Abstract][Full Text] [Related]
25. Aryl Hydrocarbon Receptor Interacting Protein Maintains Germinal Center B Cells through Suppression of BCL6 Degradation.
Sun D; Stopka-Farooqui U; Barry S; Aksoy E; Parsonage G; Vossenkämper A; Capasso M; Wan X; Norris S; Marshall JL; Clear A; Gribben J; MacDonald TT; Buckley CD; Korbonits M; Haworth O
Cell Rep; 2019 Apr; 27(5):1461-1471.e4. PubMed ID: 31042473
[TBL] [Abstract][Full Text] [Related]
26. The role of BCL6 in lymphomas and routes to therapy.
Wagner SD; Ahearne M; Ko Ferrigno P
Br J Haematol; 2011 Jan; 152(1):3-12. PubMed ID: 21083654
[TBL] [Abstract][Full Text] [Related]
27. Sequential transcription factor targeting for diffuse large B-cell lymphomas.
Cerchietti LC; Polo JM; Da Silva GF; Farinha P; Shaknovich R; Gascoyne RD; Dowdy SF; Melnick A
Cancer Res; 2008 May; 68(9):3361-9. PubMed ID: 18451163
[TBL] [Abstract][Full Text] [Related]
28. Proteolysis Targeting Chimeras for the Selective Degradation of Mcl-1/Bcl-2 Derived from Nonselective Target Binding Ligands.
Wang Z; He N; Guo Z; Niu C; Song T; Guo Y; Cao K; Wang A; Zhu J; Zhang X; Zhang Z
J Med Chem; 2019 Sep; 62(17):8152-8163. PubMed ID: 31389699
[TBL] [Abstract][Full Text] [Related]
29. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH
Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234
[TBL] [Abstract][Full Text] [Related]
30. Achieving
Bellenie BR; Cheung KJ; Varela A; Pierrat OA; Collie GW; Box GM; Bright MD; Gowan S; Hayes A; Rodrigues MJ; Shetty KN; Carter M; Davis OA; Henley AT; Innocenti P; Johnson LD; Liu M; de Klerk S; Le Bihan YV; Lloyd MG; McAndrew PC; Shehu E; Talbot R; Woodward HL; Burke R; Kirkin V; van Montfort RLM; Raynaud FI; Rossanese OW; Hoelder S
J Med Chem; 2020 Apr; 63(8):4047-4068. PubMed ID: 32275432
[TBL] [Abstract][Full Text] [Related]
31. Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals).
Schiedel M; Herp D; Hammelmann S; Swyter S; Lehotzky A; Robaa D; Oláh J; Ovádi J; Sippl W; Jung M
J Med Chem; 2018 Jan; 61(2):482-491. PubMed ID: 28379698
[TBL] [Abstract][Full Text] [Related]
32. Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders.
Su S; Yang Z; Gao H; Yang H; Zhu S; An Z; Wang J; Li Q; Chandarlapaty S; Deng H; Wu W; Rao Y
J Med Chem; 2019 Aug; 62(16):7575-7582. PubMed ID: 31330105
[TBL] [Abstract][Full Text] [Related]
33. Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
Jerkeman M; Aman P; Cavallin-Stahl E; Torlakovic E; Akerman M; Mitelman F; Fioretos T
Int J Oncol; 2002 Jan; 20(1):161-5. PubMed ID: 11743658
[TBL] [Abstract][Full Text] [Related]
34. Discovery of a B-Cell Lymphoma 6 Protein-Protein Interaction Inhibitor by a Biophysics-Driven Fragment-Based Approach.
Kamada Y; Sakai N; Sogabe S; Ida K; Oki H; Sakamoto K; Lane W; Snell G; Iida M; Imaeda Y; Sakamoto J; Matsui J
J Med Chem; 2017 May; 60(10):4358-4368. PubMed ID: 28471657
[TBL] [Abstract][Full Text] [Related]
35. Lenalidomide modulates gene expression in human ABC-DLBCL cells by regulating IKAROS interaction with an intronic control region of SPIB.
Solomon LA; Batista CR; DeKoter RP
Exp Hematol; 2017 Dec; 56():46-57.e1. PubMed ID: 28893618
[TBL] [Abstract][Full Text] [Related]
36. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
Li X; Song Y
J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
[TBL] [Abstract][Full Text] [Related]
37. Folate-Guided Protein Degradation by Immunomodulatory Imide Drug-Based Molecular Glues and Proteolysis Targeting Chimeras.
Chen H; Liu J; Kaniskan HÜ; Wei W; Jin J
J Med Chem; 2021 Aug; 64(16):12273-12285. PubMed ID: 34378936
[TBL] [Abstract][Full Text] [Related]
38. BCL6 as a therapeutic target for lymphoma.
Leeman-Neill RJ; Bhagat G
Expert Opin Ther Targets; 2018 Feb; 22(2):143-152. PubMed ID: 29262721
[TBL] [Abstract][Full Text] [Related]
39. Cyclin D1-positive diffuse large B-cell lymphoma with IGH-CCND1 translocation and BCL6 rearrangement: a report of two cases.
Al-Kawaaz M; Mathew S; Liu Y; Gomez ML; Chaviano F; Knowles DM; Orazi A; Tam W
Am J Clin Pathol; 2015 Feb; 143(2):288-99. PubMed ID: 25596256
[TBL] [Abstract][Full Text] [Related]
40. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ
Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
